Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

RICA (ERAS) Pathway Adherence and Early Discharge Feasibility After Urgent Uncomplicated Appendectomy (APENERAS) (APENERAS)

3. November 2026 aktualisiert von: Susana Postigo Morales, Hospital Galdakao-Usansolo

APENERAS: Eine prospektive multizentrische Beobachtungsstudie zur Einhaltung des RICA (ERAS)-Pfades, zu Sicherheitsergebnissen und zur Machbarkeit einer frühzeitigen Entlassung bei Erwachsenen, die sich einer dringenden, unkomplizierten Appendektomie unterziehen

This multicenter, prospective observational study (APENERAS) evaluates adherence to the RICA (ERAS Zaragoza 2022) perioperative care pathway in adults undergoing urgent laparoscopic appendectomy for uncomplicated acute appendicitis. The study aims to describe real-world adherence to the pathway across participating hospitals and to explore its association with patient safety and recovery outcomes.

Key outcomes include postoperative complications (including severity), length of hospital stay, and readmissions within 30 days. Patient-reported satisfaction is also assessed using a structured survey. In addition, the study evaluates the feasibility of early discharge/ambulatory management by intention-to-treat, using a standardized checklist of clinical, functional, and social discharge criteria assessed during the first 24 hours after surgery.

No changes to usual clinical care are introduced. Data are collected from routine perioperative management and follow-up.

Studienübersicht

Detaillierte Beschreibung

APENERAS is a prospective, multicenter observational study conducted in adult patients undergoing urgent laparoscopic appendectomy for uncomplicated acute appendicitis. The study assesses real-world adherence to the RICA (ERAS Zaragoza 2022) pathway, a structured set of perioperative recommendations intended to optimize recovery and standardize care in urgent surgery settings.

The primary objective is to quantify overall adherence and adherence by individual components of the pathway. Secondary objectives include evaluating the association between adherence and (1) postoperative safety outcomes (complications and severity classification), (2) efficiency outcomes (length of stay), (3) unplanned healthcare use (readmissions within 30 days), and (4) patient experience (satisfaction survey completed at discharge). In addition, feasibility of early discharge/ambulatory management is assessed by intention-to-treat using a standardized discharge-readiness checklist (clinical stability, pain control with oral analgesia, oral tolerance, mobilization, spontaneous urination, wound status, and social support), evaluated during the first postoperative day.

Candidate profiles for early discharge are also explored using established clinical prediction tools (e.g., Saint-Antoine Score), together with demographic and clinical covariates. Follow-up is performed up to 30 days after surgery to capture postoperative events and readmissions.

This study does not involve any experimental intervention, drug, or device, and does not require changes to standard clinical practice. It is based on systematic data collection from routine care processes and clinical records in each participating center.

Studientyp

Beobachtungs

Einschreibung (Tatsächlich)

199

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Alicante
      • Elche, Alicante, Spanien, 03203
        • Hospital General Universitario de Elche
    • Barcelona
      • Igualada, Barcelona, Spanien, 08700
        • Hospital Universitari d'Igualada
      • Sabadell, Barcelona, Spanien, 08208
        • Hospital Universitari Parc Taulí
    • Vizcaya
      • Galdakao, Vizcaya, Spanien, 48960
        • Hospital Galdakao-Usansolo

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Adults aged 18-75 years undergoing urgent laparoscopic appendectomy for uncomplicated acute appendicitis in participating hospitals. The study evaluates adherence to the RICA (ERAS Zaragoza 2022) pathway in routine clinical practice, early discharge feasibility (8, 12, and 24 hours after surgery), and safety outcomes (complications, readmissions, reinterventions, and mortality) up to 30 days after surgery. No experimental intervention is introduced.

Beschreibung

Inclusion Criteria:

  • Age ≥ 18 and ≤ 75 years.
  • Immunocompetent patients.
  • ASA physical status I-III.
  • Preoperative diagnosis of uncomplicated acute appendicitis (based on clinical assessment, laboratory tests, and imaging such as ultrasound and/or CT according to availability).
  • Indication for urgent appendectomy for uncomplicated appendicitis.
  • Laparoscopic approach.
  • Expected operative time < 90 minutes.
  • Cooperative patient able to understand and follow instructions.
  • Voluntary participation and written informed consent.
  • Adequate social/family support (availability of a responsible adult for transport home and support during the first postoperative days).
  • Travel time from home to hospital < 1 hour and access to transportation.
  • Acceptable home environment for recovery (telephone access and basic habitability/hygiene).

Exclusion Criteria:

  • ASA physical status IV.
  • Age < 18 years or > 75 years.
  • BMI > 35 kg/m² with significant respiratory or cardiovascular complications.
  • Ischemic heart disease class IV or acute myocardial infarction within the last 6 months.
  • Congestive heart failure NYHA class III-IV.
  • Sleep apnea or severe COPD, or need for home oxygen therapy.
  • Poorly controlled diabetes mellitus.
  • Severe psychiatric disorders, drug addiction, or severe alcoholism.
  • History of major anesthesia-related complications or malignant hyperthermia.
  • Epilepsy.
  • Pregnancy.
  • Use of anticoagulants, MAO inhibitors, systemic corticosteroids, or immunosuppressive drugs.
  • Complicated appendicitis (gangrenous or perforated appendicitis, abscess, diffuse peritonitis).
  • Severe sepsis.
  • Primary open appendectomy or conversion to open surgery.
  • Positive SARS-CoV-2 PCR or symptoms compatible with COVID-19.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Urgent Uncomplicated Appendectomy Cohort

Adults undergoing urgent laparoscopic appendectomy for uncomplicated acute appendicitis in participating hospitals. Perioperative management follows routine clinical practice. The adherence to the RICA (ERAS) pathway items is assessed, along with safety outcomes and early discharge feasibility.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Overall adherence to the RICA (ERAS Zaragoza 2022) pathway
Zeitfenster: From day of surgery through postoperative day 1 or hospital discharge (whichever occurs first).

Overall adherence will be quantified as the proportion (%) of prespecified RICA (ERAS Zaragoza 2022) items fulfilled per participant and overall, using the study case report form. Adherence will be reported as a global percentage and by individual pathway components.

From day of surgery through postoperative day 1 or hospital discharge (whichever occurs first).

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Early discharge feasibility at 8, 12 and 24 hours after surgery
Zeitfenster: 8, 12 and 24 hours after surgery.

Feasibility of early discharge will be assessed by intention-to-treat using a standardized discharge-readiness checklist (clinical stability, respiratory stability, orientation, mobility, oral intake, urination, wound status, and social support/logistics). The proportion of patients meeting all criteria at each timepoint (8h, 12h, 24h) will be reported.

8, 12 and 24 hours after surgery.
Postoperative complications and severity (Clavien-Dindo)
Zeitfenster: Up to 30 days after surgery.

Postoperative complications will be recorded and graded according to the Clavien-Dindo classification.

Up to 30 days after surgery.
Length of hospital stay
Zeitfenster: From surgery to hospital discharge, assessed up to 30 days after surgery.

Length of stay will be measured as time from surgery to hospital discharge (reported in days and/or hours as available).

From surgery to hospital discharge, assessed up to 30 days after surgery.
Readmission within 30 days
Zeitfenster: Up to 30 days after surgery.

Unplanned readmissions for any cause will be recorded.

Up to 30 days after surgery.
Patient satisfaction score
Zeitfenster: Up to 30 days after surgery.

Patient satisfaction will be assessed using a structured survey delivered at hospital discharge and collected during postoperative follow-up. The overall satisfaction score (0-10 scale) and relevant domains will be analyzed. Higher scores indicate greater patient satisfaction.

Up to 30 days after surgery.
Saint-Antoine Score for early discharge eligibility prediction within 24 hours after surgery
Zeitfenster: Baseline (preoperative; assessed immediately before surgery).

The Saint-Antoine Score is a 5-point preoperative clinical score (range: 0 to 5) calculated at baseline (immediately before surgery) as the sum of five low-risk criteria (each criterion = 1 point; total score 0-5). Higher scores indicate a greater likelihood of eligibility for unplanned early discharge within 24 hours (better discharge readiness/lower-risk profile). Lower scores indicate a lower likelihood of early discharge eligibility. Predictive performance will be described (e.g., proportion eligible across score categories and discrimination metrics, as applicable).

Baseline (preoperative; assessed immediately before surgery).
Reintervention within 30 days
Zeitfenster: Up to 30 days after surgery.

Any unplanned reintervention after the index appendectomy, including surgical reoperation (e.g., re-laparoscopy/laparotomy) and other invasive procedures (e.g., percutaneous drainage), will be recorded.

Up to 30 days after surgery.
All-cause mortality within 30 days
Zeitfenster: Up to 30 days after surgery.

All-cause mortality will be recorded.

Up to 30 days after surgery.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Studienleiter: Bakarne Ugarte-Sierra, PhD, Grupo español de rehabilitación multimodal (GERM)
  • Studienleiter: José Manuel Ramírez-Rodríguez, PhD, Grupo español de rehabilitación multimodal (GERM)

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

7. Dezember 2022

Primärer Abschluss (Tatsächlich)

27. Januar 2025

Studienabschluss (Tatsächlich)

26. Februar 2025

Studienanmeldedaten

Zuerst eingereicht

14. Januar 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

6. Februar 2026

Zuerst gepostet (Tatsächlich)

10. Februar 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

6. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

3. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

De-identified individual participant data (IPD) underlying the results reported in publications will be shared. The shared dataset will contain coded study IDs and will exclude direct identifiers (e.g., name, medical record number, address). Variables will be minimized/modified as needed to reduce re-identification risk in accordance with GDPR and institutional policies.

IPD-Sharing-Zeitrahmen

Available beginning 12 months after publication of the primary results and for 5 years thereafter.

IPD-Sharing-Zugriffskriterien

Access will be granted to researchers with a clear research question and an appropriate analysis plan, subject to review and approval by the study team and compliance with GDPR and applicable institutional policies. Data will be provided in de-identified form after completion of a data sharing agreement. Requests should be submitted by email to: estudioapeneras@gmail.com

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren